Agile R100 is a benchtop label-free assay that cuts out numerous steps typical of an ELISA, and provides kinetic binding data in agreement with the Octet at a fraction of the cost.
San Diego, CA (PRWEB)
June 20, 2017
Nanomedical Diagnostics, a life science company pioneering label-free graphene biosensors for use in drug discovery, today announced that the paper, “Towards Novel Graphene-Enabled Diagnostic Assays with Improved Signal-to-Noise Ratio,” which features Agile R100’s significant increase in signal-to-noise ratio over Bio-Layer Interferometry (BLI) and ELISA platforms, has been published in MRS Advances, a journal that highlights new and emerging science. The paper compares Zika antigen detection on an Agile R100 versus an Octet RED96, a BLI platform. It also compares measurement of an inflammatory protein, IL-6, with an Agile R100 versus with an Invitrogen ELISA kit.
While BLI and ELISA are widely used in drug discovery and disease diagnostics, the platforms suffer noise interference at ultra-low concentrations, which reduces measurement sensitivity. Highly-sensitive measurements are necessary to develop biopharmaceuticals at therapeutically-relevant levels and to gain accurate early clinical results. In this study, Agile R100 exhibited detection of Zika viral antigen at a concentration 10 times lower than on the Octet RED96, a standard kinetic binding drug discovery platform. Similarly, Agile R100 lowered the limit of detection for inflammatory protein IL-6 by 10 times, versus on an ELISA, a conventional tool for clinical diagnostics.
“This study has broad-ranging healthcare implications,” says Nanomedical Diagnostics CEO, Ross Bundy. “The Octet is an expensive machine that is costly to run,…